Cardiovascular effects of E4080, a novel bradycardiac agent with coronary vasodilating properties, in anesthetized dogs
| Autor: | Ogawa Toshiaki, Kawamura Takanori, Adachi Hideyuki |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
Bradycardia Cardiac output medicine.medical_specialty Cardiotonic Agents Potassium Channels Vasodilator Agents Catechols Hemodynamics Vasodilation Glibenclamide Electrocardiography Dogs Oxygen Consumption Coronary Circulation Internal medicine Glyburide medicine Animals Channel blocker Sinoatrial Node Pharmacology business.industry Myocardium Imidazoles Mean Aortic Pressure Oxygen Ventricular pressure Cardiology Female medicine.symptom business medicine.drug |
| Zdroj: | European Journal of Pharmacology. 203:399-404 |
| ISSN: | 0014-2999 |
| DOI: | 10.1016/0014-2999(91)90897-y |
| Popis: | The cardiohemodynamic effects of E4080, a novel bradycardiac agent with a coronary vasodilating feature, were studied in anesthetized open-chest dogs. E4080 (0.3 and l mg/kg i.v.) decreased heart rate (HR), mean aortic pressure (MAP) and total peripheral resistance, and increased coronary blood flow (CBF) without affecting cardiac output and the electrocardiogram. The maximum rate of rise in left ventricular pressure decreased at 1mg/kg. In addition, E4080 (0.3 and 1mg/kg i.v.) decreased myocardial oxygen consumption. On administration in sinus node artery, E4080 (10 and 30 μg) selectively decreased HR. Glibenclamide, an ATP-sensitivc K+ channel blocker (5 mg/kg i.v.), inhibited both the increase in CBF and the decrease in MAP caused by E4080 (l mg/kg i.v.) but did not inhibit the bradycardia. These results suggested that E4080 has both bradycardiac and coronary vasodilating effects, and that activation of ATP-sensitive K+ channel contributes to the vasodilating action of E4080 but not to the bradycardiac action. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|